iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC on October 23, 2024, updating its corporate presentation. The presentation, furnished as Exhibit 99.1, includes forward-looking statements and covers the company's transition from a plant-based CDMO with a focus on COVID vaccines to a machine learning biotech company. iBio's updated strategy involves entering the metabolic disease space and building a leading biologics company. The company has raised significant funds, established partnerships with Eli Lilly and NIH, and sold its GMP facility. The presentation highlights iBio's patented machine learning technology for antibody discovery, aiming to address challenges in the antibody market projected to reach $612 billion by 2032. The company's preclinical pipeline includes programs targeting...Show More

iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC on October 23, 2024, updating its corporate presentation. The presentation, furnished as Exhibit 99.1, includes forward-looking statements and covers the company's transition from a plant-based CDMO with a focus on COVID vaccines to a machine learning biotech company. iBio's updated strategy involves entering the metabolic disease space and building a leading biologics company. The company has raised significant funds, established partnerships with Eli Lilly and NIH, and sold its GMP facility. The presentation highlights iBio's patented machine learning technology for antibody discovery, aiming to address challenges in the antibody market projected to reach $612 billion by 2032. The company's preclinical pipeline includes programs targeting hard-to-drug molecules with a focus on immuno-oncology and cardiometabolic diseases. iBio's technology stack is designed to accelerate discovery and improve the success rate of antibody development. The company's business model includes strategic partnerships, proprietary preclinical pipeline licensing, and platform licensing for specific disease areas. iBio's leadership team boasts extensive industry experience, and the company's financial highlights indicate a cash runway through June 2025.